Titre : Syndécane-2

Syndécane-2 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Workforce
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Syndécane-2 : Questions médicales les plus fréquentes", "headline": "Syndécane-2 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Syndécane-2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-14", "dateModified": "2025-05-09", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Syndécane-2" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Syndécanes", "url": "https://questionsmedicales.fr/mesh/D053667", "about": { "@type": "MedicalCondition", "name": "Syndécanes", "code": { "@type": "MedicalCode", "code": "D053667", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.550.847" } } }, "about": { "@type": "MedicalCondition", "name": "Syndécane-2", "alternateName": "Syndecan-2", "code": { "@type": "MedicalCode", "code": "D053669", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Eok-Soo Oh", "url": "https://questionsmedicales.fr/author/Eok-Soo%20Oh", "affiliation": { "@type": "Organization", "name": "Department of Life Sciences, College of Natural Sciences, Ewha Womans University, Seoul 03760, Korea." } }, { "@type": "Person", "name": "Anett Hudák", "url": "https://questionsmedicales.fr/author/Anett%20Hud%C3%A1k", "affiliation": { "@type": "Organization", "name": "Pharmacoidea Ltd., H-6726 Szeged, Hungary." } }, { "@type": "Person", "name": "Tamás Letoha", "url": "https://questionsmedicales.fr/author/Tam%C3%A1s%20Letoha", "affiliation": { "@type": "Organization", "name": "Pharmacoidea Ltd., H-6726 Szeged, Hungary." } }, { "@type": "Person", "name": "Bohee Jang", "url": "https://questionsmedicales.fr/author/Bohee%20Jang", "affiliation": { "@type": "Organization", "name": "Department of Life Sciences, College of Natural Sciences, Ewha Womans University, Seoul 03760, Korea." } }, { "@type": "Person", "name": "Annamária Letoha", "url": "https://questionsmedicales.fr/author/Annam%C3%A1ria%20Letoha", "affiliation": { "@type": "Organization", "name": "Department of Medicine, Albert Szent-Györgyi Clinical Center, Faculty of Medicine, University of Szeged, H-6725 Szeged, Hungary." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "A national analysis of the pharmacy workforce in Indonesia.", "datePublished": "2022-09-29", "url": "https://questionsmedicales.fr/article/36175892", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12960-022-00767-4" } }, { "@type": "ScholarlyArticle", "name": "The physiotherapy workforce in Nepal: A national survey.", "datePublished": "2022-07-13", "url": "https://questionsmedicales.fr/article/35822869", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/jep.13729" } }, { "@type": "ScholarlyArticle", "name": "Structural determinants of health workforce burnout.", "datePublished": "2022-05-22", "url": "https://questionsmedicales.fr/article/35603868", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1177/08404704221093889" } }, { "@type": "ScholarlyArticle", "name": "Managing uncertainty in forecasting health workforce demand using the Robust Workforce Planning Framework: the example of midwives in Belgium.", "datePublished": "2023-09-18", "url": "https://questionsmedicales.fr/article/37723568", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12960-023-00861-1" } }, { "@type": "ScholarlyArticle", "name": "A resilient workforce: patient safety and the workforce response to a cyber-attack on the ICT systems of the national health service in Ireland.", "datePublished": "2023-10-17", "url": "https://questionsmedicales.fr/article/37848947", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12913-023-10076-8" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines membranaires", "item": "https://questionsmedicales.fr/mesh/D008565" }, { "@type": "ListItem", "position": 5, "name": "Glycoprotéines membranaires", "item": "https://questionsmedicales.fr/mesh/D008562" }, { "@type": "ListItem", "position": 6, "name": "Syndécanes", "item": "https://questionsmedicales.fr/mesh/D053667" }, { "@type": "ListItem", "position": 7, "name": "Syndécane-2", "item": "https://questionsmedicales.fr/mesh/D053669" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Syndécane-2 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Syndécane-2", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-14", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Syndécane-2", "description": "Comment diagnostiquer une anomalie de Syndécane-2 ?\nQuels examens sont recommandés pour le Syndécane-2 ?\nLe dosage sanguin est-il utile pour le Syndécane-2 ?\nQuels marqueurs sont associés au Syndécane-2 ?\nY a-t-il des tests spécifiques pour le Syndécane-2 ?", "url": "https://questionsmedicales.fr/mesh/D053669?mesh_terms=Workforce&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Syndécane-2", "description": "Quels symptômes sont liés à une dysfonction de Syndécane-2 ?\nLe Syndécane-2 affecte-t-il la croissance tumorale ?\nY a-t-il des signes cliniques associés au Syndécane-2 ?\nLe Syndécane-2 est-il lié à des maladies spécifiques ?\nComment le Syndécane-2 influence-t-il la signalisation cellulaire ?", "url": "https://questionsmedicales.fr/mesh/D053669?mesh_terms=Workforce&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Syndécane-2", "description": "Peut-on prévenir les anomalies de Syndécane-2 ?\nY a-t-il des mesures préventives spécifiques ?\nL'alimentation influence-t-elle le Syndécane-2 ?\nLe tabagisme affecte-t-il le Syndécane-2 ?\nL'exercice physique a-t-il un impact sur le Syndécane-2 ?", "url": "https://questionsmedicales.fr/mesh/D053669?mesh_terms=Workforce&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Syndécane-2", "description": "Quels traitements ciblent le Syndécane-2 ?\nLe Syndécane-2 peut-il être une cible thérapeutique ?\nY a-t-il des médicaments associés au Syndécane-2 ?\nComment les thérapies géniques affectent-elles le Syndécane-2 ?\nLe Syndécane-2 est-il impliqué dans des essais cliniques ?", "url": "https://questionsmedicales.fr/mesh/D053669?mesh_terms=Workforce&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Syndécane-2", "description": "Quelles complications peuvent survenir avec le Syndécane-2 ?\nLe Syndécane-2 est-il lié à des complications cardiovasculaires ?\nComment le Syndécane-2 affecte-t-il la réponse immunitaire ?\nY a-t-il des complications liées à la thérapie ciblée du Syndécane-2 ?\nLe Syndécane-2 influence-t-il la progression des maladies ?", "url": "https://questionsmedicales.fr/mesh/D053669?mesh_terms=Workforce&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Syndécane-2", "description": "Quels sont les facteurs de risque pour le Syndécane-2 ?\nL'âge influence-t-il le Syndécane-2 ?\nLe stress a-t-il un impact sur le Syndécane-2 ?\nY a-t-il des prédispositions génétiques au Syndécane-2 ?\nL'environnement joue-t-il un rôle dans le Syndécane-2 ?", "url": "https://questionsmedicales.fr/mesh/D053669?mesh_terms=Workforce&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une anomalie de Syndécane-2 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses de tissus peuvent être utilisés pour évaluer les niveaux de Syndécane-2." } }, { "@type": "Question", "name": "Quels examens sont recommandés pour le Syndécane-2 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des biopsies et des analyses immunohistochimiques peuvent aider à diagnostiquer les anomalies." } }, { "@type": "Question", "name": "Le dosage sanguin est-il utile pour le Syndécane-2 ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Le dosage sanguin peut fournir des informations sur les niveaux de Syndécane-2 dans certaines conditions." } }, { "@type": "Question", "name": "Quels marqueurs sont associés au Syndécane-2 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des marqueurs tumoraux et des cytokines peuvent être associés à l'expression de Syndécane-2." } }, { "@type": "Question", "name": "Y a-t-il des tests spécifiques pour le Syndécane-2 ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des tests spécifiques d'immunofluorescence peuvent être utilisés pour détecter Syndécane-2." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une dysfonction de Syndécane-2 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent inclure des troubles de l'adhésion cellulaire et des anomalies tissulaires." } }, { "@type": "Question", "name": "Le Syndécane-2 affecte-t-il la croissance tumorale ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une expression anormale de Syndécane-2 peut influencer la croissance et la métastase tumorale." } }, { "@type": "Question", "name": "Y a-t-il des signes cliniques associés au Syndécane-2 ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des signes cliniques peuvent inclure des inflammations et des modifications dans la matrice extracellulaire." } }, { "@type": "Question", "name": "Le Syndécane-2 est-il lié à des maladies spécifiques ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il est impliqué dans des maladies comme le cancer et certaines maladies inflammatoires." } }, { "@type": "Question", "name": "Comment le Syndécane-2 influence-t-il la signalisation cellulaire ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Il modifie la signalisation cellulaire en interagissant avec des récepteurs et des ligands." } }, { "@type": "Question", "name": "Peut-on prévenir les anomalies de Syndécane-2 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par un mode de vie sain et la réduction des facteurs de risque associés." } }, { "@type": "Question", "name": "Y a-t-il des mesures préventives spécifiques ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Des dépistages réguliers et une surveillance des maladies associées peuvent aider à la prévention." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle le Syndécane-2 ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée peut influencer l'expression de Syndécane-2 et la santé cellulaire." } }, { "@type": "Question", "name": "Le tabagisme affecte-t-il le Syndécane-2 ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut altérer l'expression de Syndécane-2 et augmenter le risque de maladies." } }, { "@type": "Question", "name": "L'exercice physique a-t-il un impact sur le Syndécane-2 ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "L'exercice régulier peut améliorer la santé cellulaire et potentiellement réguler Syndécane-2." } }, { "@type": "Question", "name": "Quels traitements ciblent le Syndécane-2 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies ciblées et des anticorps monoclonaux peuvent être développés pour cibler Syndécane-2." } }, { "@type": "Question", "name": "Le Syndécane-2 peut-il être une cible thérapeutique ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, en raison de son rôle dans la progression tumorale, il est une cible potentielle pour des traitements." } }, { "@type": "Question", "name": "Y a-t-il des médicaments associés au Syndécane-2 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments expérimentaux ciblant la signalisation de Syndécane-2 sont en développement." } }, { "@type": "Question", "name": "Comment les thérapies géniques affectent-elles le Syndécane-2 ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les thérapies géniques peuvent corriger les anomalies d'expression de Syndécane-2 dans certaines pathologies." } }, { "@type": "Question", "name": "Le Syndécane-2 est-il impliqué dans des essais cliniques ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des essais cliniques évaluent des traitements ciblant Syndécane-2 dans divers cancers." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec le Syndécane-2 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des troubles de la cicatrisation et des métastases dans le cancer." } }, { "@type": "Question", "name": "Le Syndécane-2 est-il lié à des complications cardiovasculaires ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des études suggèrent un lien entre Syndécane-2 et des complications cardiovasculaires." } }, { "@type": "Question", "name": "Comment le Syndécane-2 affecte-t-il la réponse immunitaire ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Une dysfonction de Syndécane-2 peut altérer la réponse immunitaire, augmentant le risque d'infections." } }, { "@type": "Question", "name": "Y a-t-il des complications liées à la thérapie ciblée du Syndécane-2 ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des effets secondaires peuvent survenir avec les thérapies ciblées, nécessitant une surveillance." } }, { "@type": "Question", "name": "Le Syndécane-2 influence-t-il la progression des maladies ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une expression anormale peut accélérer la progression de certaines maladies, comme le cancer." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour le Syndécane-2 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des prédispositions génétiques, le tabagisme et l'obésité." } }, { "@type": "Question", "name": "L'âge influence-t-il le Syndécane-2 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'âge peut affecter l'expression de Syndécane-2 et le risque de maladies associées." } }, { "@type": "Question", "name": "Le stress a-t-il un impact sur le Syndécane-2 ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Le stress chronique peut influencer l'expression de Syndécane-2 et la santé cellulaire." } }, { "@type": "Question", "name": "Y a-t-il des prédispositions génétiques au Syndécane-2 ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines mutations génétiques peuvent augmenter le risque d'anomalies de Syndécane-2." } }, { "@type": "Question", "name": "L'environnement joue-t-il un rôle dans le Syndécane-2 ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des toxines environnementales peut affecter l'expression de Syndécane-2." } } ] } ] }

Sources (1641 au total)

A national analysis of the pharmacy workforce in Indonesia.

Pharmacists play a fundamental role in healthcare systems and achieving Universal Health Coverage (UHC) through quality primary healthcare service provision. While the World Health Organization (WHO) ... Several data sources were accessed, including a database from the National Pharmacy Committee and the professional leadership body in Indonesia. Descriptive (frequencies, percentages, and mean), corre... There were a total of 77 191 registered pharmacists in Indonesia in 2019. The pharmacists' pyramid showed a youth bulge as a general indication of market expansion in the education sector correlating ... This study signposted workforce planning gaps for policy development in Indonesia, including a need to develop structured training to support early career pharmacists in their practice. There is also ...

The physiotherapy workforce in Nepal: A national survey.

Physiotherapy is a relatively young profession in Nepal. Education standards, and workforce organization and representation have improved in recent years, but there is no detailed workforce data to su... In a cross-sectional survey, we asked Nepali physiotherapists about their sociodemographic characteristics, employment or physiotherapy practice area and settings, and job satisfaction. We assessed th... Of the 1120 physiotherapists who were contacted, 52% (female: 287; male: 293) completed the survey. The majority of the participants (75%) were less than 30 years old. The majority (73%) held a Bachel... The majority of the physiotherapy workforce in Nepal is well-educated, young and at an early career stage. Most physiotherapists work in musculoskeletal and adult neurological physiotherapy, in privat...

Managing uncertainty in forecasting health workforce demand using the Robust Workforce Planning Framework: the example of midwives in Belgium.

In Belgium, the Planning Commission for Medical Supply is responsible for monitoring human resources for health (HRH) and ultimately proposing workforce quotas. It is supported by the Planning Unit fo... The Robust Workforce Planning Framework, developed by the Centre for Workforce Intelligence in the UK was used to develop alternative midwifery workforce scenarios. The framework consists of four step... Three alternative scenarios are proposed. The first scenario (close to the current situation) envisages pregnancy and maternity care centred on gynaecologists working either in a hospital or in privat... The Robust Workforce Planning Framework provides an opportunity to adjust the modelling of the health workforce and inform decision-makers about the impact of their future decisions on the health work...

A resilient workforce: patient safety and the workforce response to a cyber-attack on the ICT systems of the national health service in Ireland.

In May 2021, the Irish public health service was the target of a cyber-attack. The response by the health service resulted in the widespread removal of access to ICT systems. While services including ... To gain an in-depth understanding of staff experiences of the cyber-attack, eight focus groups (n = 36) were conducted. Participants from a diverse range of health services were recruited, including s... The impact of the cyber-attack varied across services depending on the type of care being offered, the reliance on IT systems, and the extent of local IT support. Staff stepped-up to the challenges an... Limited contingencies within the health system IT infrastructure - what we call a lack of system resilience - was compensated for by a resilient workforce. Within the context of the prevailing COVID-1...

Rehabilitation workforce descriptors: a scoping review.

A comprehensive, accurate description of workforce capacity is important for health service planning, to ensure that health services meet local needs. In many low- to middle-income countries, the gove... A scoping review was conducted according to the five-step framework first developed by Arksey and O'Malley. The review included a broad search of literature regarding the rehabilitation workforce and ... Nineteen studies on rehabilitation workforce capacity were identified. All but one (a cross-sectional study) were database reviews. The main descriptors and indicators used to describe the rehabilitat... This scoping review provided an overview of descriptors and indicators used to describe the rehabilitation workforce capacity internationally. The study is a first step towards developing standardised... This scoping review protocol has been registered with the Open Science Framework (http://osf.10/7h6xz)....

Maintaining a strong rural dental workforce.

This study was designed to examine demographics of University of Nebraska Medical Center College of Dentistry graduates over a recent 10-year period and factors related to their choice of rural or urb... Using data from the annual Health Professions Tracking Service 2019 Dentistry Profile survey, we examined the demographic information of 169 graduates from 2009 to 2018 practicing in Nebraska at the e... This study found that some demographic variables were associated with future practice location. Specifically, a higher proportion of graduates of rural high schools chose to work in a rural location (... We found significant positive associations between dentists who chose rural practice and demographic factors such as being rural high school graduates, male, and in-state predental residents. Our find...

The Israeli anesthesiology workforce crisis: a reassessment survey.

Anesthesiologists provide crucial anesthesiology services in the operating room and non-operating room locations. Combined with an aging and growing Israeli population, there is an increasing demand f... A cross-sectional survey of demographic and professional information about each Israeli hospital anesthesiologists was solicited from 34 anesthesiology department chairs responsible for 36 Israeli acu... There are 1313 anesthesiologists in the 36 hospitals, resulting in a ratio of 14.2 anesthesiologists per 100,000 population. 22.6% of anesthesiologists will reach retirement age over the next ten year... Despite growth in the ratio of anesthesiologists per population, a workforce shortage is expected to worsen over the next ten years due to retirements, shortened call hours, and the Yatziv reform whic...

Physician assistants/associates in psychiatry: a workforce analysis.

Physician assistants/associates (PAs) provide services in diverse medical specialties globally, including psychiatry. While health professionals in psychiatry have been described for many years, littl... We describe US PAs practicing in psychiatry using robust national data from the National Commission on Certification of Physician Assistants (NCCPA). Analyses included descriptive and inferential stat... The percentage of PAs practicing in psychiatry has increased from 1.1% (n = 630) in 2013 to 2.0% (n = 2 262) in 2021. PAs in psychiatry differed from PAs practicing in all other specialties in the fol... Understanding the attributes of PAs in psychiatry is essential in medical labor supply and demand research. Our findings suggest that the number of PAs working in psychiatry is steadily increasing. Th...

Profile of the Oncology Physician Workforce and the Characteristics of Attrition.

To determine the prevalence of attrition and the frequency of transition from a primarily clinical role to an industry-related role among oncology physicians.... We tracked yearly Centers for Medicare & Medicaid Services (CMS) billing between 2015 and 2022 to estimate attrition of oncology physicians. A subanalysis of a random sample of 300 oncologists with fe... Of the 16,870 oncologists who billed to CMS in 2015, 3,558 (21%) had stopped billing by 2022. Among a randomly selected 300 oncologists, we found current employment information for 223 (74%); 78 of th... By 2022, 21% of oncology physicians billing to CMS in 2015 had stopped. 78 of the 300 sampled physicians were found to be working in industry. In total, 1 in 17 oncologists (5%) moved to industry over...